Klinički ishodi

Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. (otvara se novi prozor)

Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Carpenter N, Mehta B, Franklin J, Giagounidis A

Izvor‎: Lancet Haematol 2018;5(3):e117-e126.

Indeks‎: PubMed 29396092

DOI‎: 10.1016/S2352-3026(18)30016-4

https://www.ncbi.nlm.nih.gov/pubmed/29396092 (otvara se novi prozor)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (otvara se novi prozor)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Izvor‎: Cancer 2013;119(1):107-14.

Indeks‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (otvara se novi prozor)

HEMATOLOGIJA

Klinički ishodi

hrvatski

Klinički ishodi

https://assetsnffrgf-a.akamaihd.net/assets/ct/1add6d1d93/images/syn_placeholder_sqr.png

Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. (otvara se novi prozor)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (otvara se novi prozor)

Odbor za kontaktiranje s bolnicama (OKB)

Preuzmite medicinske informacije

Filmovi

Klinički ishodi

Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. (otvara se novi prozor)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (otvara se novi prozor)

Odbor za kontaktiranje s bolnicama (OKB)

Preuzmite medicinske informacije

Filmovi

Izaberi svoj jezik

Podijeli